Matches in Nanopublications for { ?s ?p "[Pharmacological or dominant-negative JNK inhibition restricts DLBCL survival in vitro and in vivo and synergizes strongly with the Bruton's tyrosine kinase inhibitor ibrutinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- assertion description "[Pharmacological or dominant-negative JNK inhibition restricts DLBCL survival in vitro and in vivo and synergizes strongly with the Bruton's tyrosine kinase inhibitor ibrutinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1276273.RA1pt0GEv8PIqgTHaNxqzhNFIEt5VdD5B3Ybxpn7rLU6I130_assertion description "[Pharmacological or dominant-negative JNK inhibition restricts DLBCL survival in vitro and in vivo and synergizes strongly with the Bruton's tyrosine kinase inhibitor ibrutinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1276273.RA1pt0GEv8PIqgTHaNxqzhNFIEt5VdD5B3Ybxpn7rLU6I130_provenance.